prednisone has been researched along with Aging in 52 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the present study, the antiemetic effect of palonosetron, not combined with dexamethasone and aprepitant, on chemotherapy-induced nausea and vomiting was evaluated in patients with malignant lymphoma receiving first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, and was compared to that of granisetron." | 7.85 | Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP. ( Akashi, K; Kadoyama, K; Kamezaki, K; Kato, K; Miyamoto, T; Mori, Y; Nakamura, T; Shiratsuchi, M; Takenaka, K; Uchida, M, 2017) |
| "The pharmacokinetics of a 40-mg intravenous dose of prednisolone were determined in 10 steroid-dependent asthmatic children with highly variable prednisone requirements (5 mg every other day to 40 mg a day)." | 7.66 | Prednisolone disposition in steroid-dependent asthmatic children. ( Ellis, EF; Jusko, WJ; Middleton, E; Nickelsen, JA; Rose, JQ, 1981) |
| "Synthetic 1alpha-hydroxycholecalciferol, a potent vitamin D analogue, was given daily together with calcium to seven patients with senile osteoporosis and to three patients with prednisone-induced bone loss." | 7.65 | Effect of 1alpha-hydroxycholecalciferol in senile osteoporosis and in bone loss following prednisone treatment. ( Andersen, RB; Friis, TH; Hjorth, L; Kjaer, I; Lund, B; Reimann, I; Sorensen, OH, 1977) |
| "Both of the enzymes were detectable in blister fluid and serum, but their expression varied." | 5.29 | Influence of aging, localization, glucocorticoids and isotretinoin on matrix metalloproteases 2 (MMP-2) and 9 (MMP-9) in suction blister fluids. ( Autio, P; Kylmäniemio, M; Oikarinen, A, 1995) |
| "In the present study, the antiemetic effect of palonosetron, not combined with dexamethasone and aprepitant, on chemotherapy-induced nausea and vomiting was evaluated in patients with malignant lymphoma receiving first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, and was compared to that of granisetron." | 3.85 | Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP. ( Akashi, K; Kadoyama, K; Kamezaki, K; Kato, K; Miyamoto, T; Mori, Y; Nakamura, T; Shiratsuchi, M; Takenaka, K; Uchida, M, 2017) |
| " Multivariate analyses identified the following factors to be associated with fracturing: years taking prednisone, previous diagnosis of osteoporosis, disability, age, lack of physical activity, female sex, disease duration, impaired grip strength, and low body mass." | 3.68 | Fractures in rheumatoid arthritis: an evaluation of associated risk factors. ( Bloch, DA; Fries, JF; Michel, BA; Wolfe, F, 1993) |
| "The pharmacokinetics of a 40-mg intravenous dose of prednisolone were determined in 10 steroid-dependent asthmatic children with highly variable prednisone requirements (5 mg every other day to 40 mg a day)." | 3.66 | Prednisolone disposition in steroid-dependent asthmatic children. ( Ellis, EF; Jusko, WJ; Middleton, E; Nickelsen, JA; Rose, JQ, 1981) |
| "Synthetic 1alpha-hydroxycholecalciferol, a potent vitamin D analogue, was given daily together with calcium to seven patients with senile osteoporosis and to three patients with prednisone-induced bone loss." | 3.65 | Effect of 1alpha-hydroxycholecalciferol in senile osteoporosis and in bone loss following prednisone treatment. ( Andersen, RB; Friis, TH; Hjorth, L; Kjaer, I; Lund, B; Reimann, I; Sorensen, OH, 1977) |
| "Following recent data on multiple myeloma (MM) in the literature, a possible model of myeloma development, involving different cytokine signals, is advanced, and the prognostic significance of two principle staging systems is evaluated." | 2.40 | Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations. Part IV: Multiple myeloma and Waldenström's macroglobulinemia. ( Di Leonardo, G; Di Simone, S; Furia, N; Pasqualoni, E; Quaglino, D, 1998) |
| "Hydroxychloroquine was associated with significantly lower BPV." | 1.56 | Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus. ( Magder, LS; Petri, M; Stojan, G, 2020) |
| "The management of cancer in the older aged person is an increasingly common problem." | 1.31 | Management of cancer in the older person: a practical approach. ( Balducci, L; Extermann, M, 2000) |
| " Retarded FH was associated with higher average prednisone dosage and better FH was associated with good graft function." | 1.31 | The contribution of renal transplantation to final adult height: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). ( Fine, RN; Ho, M; Tejani, A, 2001) |
| "Pregnancy was authorized if disease was inactive on 20 mg/day prednisone or less for at least 1 yr." | 1.30 | Outcome of planned pregnancies in systemic lupus erythematosus: a prospective study on 62 pregnancies. ( Blétry, O; Darbois, Y; Godeau, P; Lê Huong, D; Lefèbvre, G; Piette, JC; Seebacher, J; Vauthier-Brouzes, D; Wechsler, B, 1997) |
| "Both of the enzymes were detectable in blister fluid and serum, but their expression varied." | 1.29 | Influence of aging, localization, glucocorticoids and isotretinoin on matrix metalloproteases 2 (MMP-2) and 9 (MMP-9) in suction blister fluids. ( Autio, P; Kylmäniemio, M; Oikarinen, A, 1995) |
| "Three patients with liver cirrhosis showed severe myelosuppression and fever." | 1.28 | [Feasibility of CHOP chemotherapy--with special reference to age, diabetes mellitus, liver cirrhosis and obesity]. ( Fujii, H; Hashimoto, S; Hiramatsu, H; Kondo, M; Kuribayashi, T; Yorozu, A, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (50.00) | 18.7374 |
| 1990's | 8 (15.38) | 18.2507 |
| 2000's | 9 (17.31) | 29.6817 |
| 2010's | 7 (13.46) | 24.3611 |
| 2020's | 2 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, RJ | 1 |
| Owens, CN | 1 |
| Drill, E | 1 |
| Iannotta, A | 1 |
| Oliveros, M | 1 |
| Schick, DL | 1 |
| Noy, A | 1 |
| Gerecitano, JF | 1 |
| Drullinsky, PR | 1 |
| Caron, PC | 1 |
| Kumar, A | 1 |
| Matasar, MJ | 1 |
| Moskowitz, C | 1 |
| Korc-Grodzicki, B | 1 |
| Zelenetz, AD | 1 |
| Salles, GA | 1 |
| Hamlin, PA | 1 |
| Arakaki, H | 1 |
| Nakazato, T | 1 |
| Osada, Y | 1 |
| Ito, C | 1 |
| Aisa, Y | 1 |
| Mori, T | 1 |
| Uchida, M | 1 |
| Mori, Y | 1 |
| Nakamura, T | 1 |
| Kato, K | 1 |
| Kamezaki, K | 1 |
| Takenaka, K | 1 |
| Shiratsuchi, M | 1 |
| Kadoyama, K | 1 |
| Miyamoto, T | 1 |
| Akashi, K | 1 |
| Moore, AS | 1 |
| Frimberger, AE | 1 |
| Stojan, G | 1 |
| Magder, LS | 1 |
| Petri, M | 1 |
| James, SF | 1 |
| Traina-Dorge, V | 1 |
| Deharo, E | 1 |
| Wellish, M | 1 |
| Palmer, BE | 1 |
| Gilden, D | 1 |
| Mahalingam, R | 1 |
| Murawski, N | 1 |
| Pfreundschuh, M | 1 |
| Zeynalova, S | 1 |
| Poeschel, V | 1 |
| Hänel, M | 1 |
| Held, G | 1 |
| Schmitz, N | 1 |
| Viardot, A | 1 |
| Schmidt, C | 1 |
| Hallek, M | 1 |
| Witzens-Harig, M | 1 |
| Trümper, L | 1 |
| Rixecker, T | 1 |
| Zwick, C | 1 |
| Kikuchi, M | 1 |
| Nakasone, H | 1 |
| Akahoshi, Y | 1 |
| Nakano, H | 1 |
| Ugai, T | 1 |
| Wada, H | 1 |
| Yamasaki, R | 1 |
| Sakamoto, K | 1 |
| Kawamura, K | 1 |
| Ishihara, Y | 1 |
| Sato, M | 1 |
| Ashizawa, M | 1 |
| Terasako-Saito, K | 1 |
| Kimura, S | 1 |
| Yamazaki, R | 1 |
| Kako, S | 1 |
| Kanda, J | 1 |
| Nishida, J | 1 |
| Sekiguchi, N | 1 |
| Noto, S | 1 |
| Kida, M | 1 |
| Hangaishi, A | 1 |
| Usuki, K | 1 |
| Kanda, Y | 1 |
| Bizikova, P | 1 |
| Linder, KE | 1 |
| Wofford, JA | 1 |
| Mamo, LB | 1 |
| Dunston, SM | 1 |
| Olivry, T | 1 |
| Jankowska-Gan, E | 1 |
| Sollinger, HW | 1 |
| Pirsch, JD | 1 |
| Cai, J | 1 |
| Pascual, J | 1 |
| Haynes, LD | 1 |
| Munoz del Rio, A | 1 |
| Burlingham, WJ | 1 |
| Paccalin, M | 1 |
| Lacotte-Thierry, L | 1 |
| Delwail, V | 1 |
| Portlock, CS | 1 |
| LAGRUE, G | 1 |
| DUCROT, H | 1 |
| HAMBURGER, J | 1 |
| LEGRAIN, M | 1 |
| PEQUIGNOT, H | 1 |
| MEYERS, MC | 1 |
| HINES, DR | 1 |
| BISHOP, RC | 1 |
| GUNN, GC | 1 |
| DOBSON, HL | 1 |
| GRAY, J | 1 |
| GEDDES, LA | 1 |
| VALLBONA, C | 1 |
| Barrs, DM | 1 |
| Ballova, V | 1 |
| Rüffer, JU | 1 |
| Haverkamp, H | 1 |
| Pfistner, B | 1 |
| Müller-Hermelink, HK | 1 |
| Dühmke, E | 1 |
| Worst, P | 1 |
| Wilhelmy, M | 1 |
| Naumann, R | 1 |
| Hentrich, M | 1 |
| Eich, HT | 1 |
| Josting, A | 1 |
| Löffler, M | 1 |
| Diehl, V | 1 |
| Engert, A | 1 |
| Freireich, EJ | 1 |
| Armitage, JO | 1 |
| Potter, JF | 1 |
| Berrih, S | 1 |
| Safar, D | 1 |
| Levasseur, P | 1 |
| Gaud, C | 1 |
| Bach, JF | 1 |
| Junker, K | 1 |
| Omura, GA | 1 |
| Moffitt, S | 1 |
| Vogler, WR | 1 |
| Salter, MM | 1 |
| Baccarani, M | 1 |
| Corbelli, G | 1 |
| Amadori, S | 1 |
| Drenthe-Schonk, A | 1 |
| Willemze, R | 1 |
| Meloni, G | 1 |
| Cardozo, PL | 1 |
| Haanen, C | 1 |
| Mandelli, F | 1 |
| Tura, S | 1 |
| Hess, CE | 1 |
| Zirkle, JW | 1 |
| Hurley, JK | 1 |
| Greenslade, T | 1 |
| Chmiel, JS | 1 |
| Szydłowska, H | 1 |
| Kowalska, Z | 1 |
| Vetulani, J | 1 |
| Rose, JQ | 1 |
| Nickelsen, JA | 1 |
| Ellis, EF | 1 |
| Middleton, E | 1 |
| Jusko, WJ | 1 |
| Kylmäniemio, M | 1 |
| Autio, P | 1 |
| Oikarinen, A | 1 |
| Peters, TG | 1 |
| Charlton, RK | 1 |
| Jones, KW | 1 |
| Goodrich, JP | 1 |
| Sill, TM | 1 |
| King, TB | 1 |
| Michel, BA | 1 |
| Bloch, DA | 1 |
| Wolfe, F | 1 |
| Fries, JF | 1 |
| Granchelli, JA | 1 |
| Avosso, DL | 1 |
| Hudecki, MS | 1 |
| Pollina, C | 1 |
| Lê Huong, D | 1 |
| Wechsler, B | 1 |
| Vauthier-Brouzes, D | 1 |
| Seebacher, J | 1 |
| Lefèbvre, G | 1 |
| Blétry, O | 1 |
| Darbois, Y | 1 |
| Godeau, P | 1 |
| Piette, JC | 1 |
| Quaglino, D | 1 |
| Di Leonardo, G | 1 |
| Pasqualoni, E | 1 |
| Furia, N | 1 |
| Di Simone, S | 1 |
| Gómez, H | 1 |
| Mas, L | 1 |
| Casanova, L | 1 |
| Pen, DL | 1 |
| Santillana, S | 1 |
| Valdivia, S | 1 |
| Otero, J | 1 |
| Rodriguez, W | 1 |
| Carracedo, C | 1 |
| Vallejos, C | 1 |
| Balducci, L | 1 |
| Extermann, M | 1 |
| Niitsu, N | 1 |
| Iijima, K | 1 |
| Fine, RN | 1 |
| Ho, M | 1 |
| Tejani, A | 1 |
| Cooper, MS | 1 |
| Rabbitt, EH | 1 |
| Goddard, PE | 1 |
| Bartlett, WA | 1 |
| Hewison, M | 1 |
| Stewart, PM | 1 |
| Sorensen, OH | 1 |
| Lund, B | 1 |
| Friis, TH | 1 |
| Hjorth, L | 1 |
| Reimann, I | 1 |
| Kjaer, I | 1 |
| Andersen, RB | 1 |
| Caldwell, CW | 1 |
| Bridges, AJ | 1 |
| Walker, SE | 1 |
| Smarr, KL | 1 |
| Reichert, RJ | 1 |
| Anderson, SK | 1 |
| Hewett, JE | 1 |
| Parker, JC | 1 |
| Kuribayashi, T | 1 |
| Kondo, M | 1 |
| Yorozu, A | 1 |
| Hiramatsu, H | 1 |
| Fujii, H | 1 |
| Hashimoto, S | 1 |
| Stuck, AE | 1 |
| Frey, BM | 1 |
| Frey, FJ | 1 |
| Amit, R | 1 |
| McKendry, RJ | 1 |
| Ducomb, DF | 1 |
| Perry, HO | 1 |
| Vasey, FB | 1 |
| Lauter, SA | 1 |
| Reece, D | 1 |
| Avioli, LV | 1 |
| Lorenzen, I | 1 |
| Zachariae, H | 1 |
| Bailey, GL | 1 |
| Mocelin, AJ | 1 |
| Griffiths, HJ | 1 |
| Zschaeck, D | 1 |
| Ghantous, WN | 1 |
| Hampers, CL | 1 |
| Merrill, JP | 1 |
| Wilson, RE | 1 |
| Hurley, RM | 1 |
| Drummond, KN | 1 |
| Jakobson, T | 1 |
| Kahanpää, A | 1 |
| Felt, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)[NCT03576378] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2018-08-08 | Active, not recruiting | ||
| Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy[NCT01626352] | Phase 2 | 22 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial[NCT01400516] | Phase 4 | 26 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial[NCT03673332] | Phase 4 | 300 participants (Anticipated) | Interventional | 2019-08-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as the time from date of first documented confirmed response to date of disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Patients who begin further anticancer therapy prior to disease progression will be censored at the date of last tumor assessment prior to the start date of the anticancer therapy. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle and every 3 months thereafter until disease progression or relapse from complete response for up to 38 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 5.6 |
Disease response assessments will be performed using the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires a disappearance of all evidence of disease. (NCT01626352)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 7 |
A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and up to 30 days after last dose, projected 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 16 |
Overall response is the number of patients with observed complete or partial response (CR or PR) as assessed using the International Working Group (IMW) revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires disappearance of all evidence of disease. Partial response requires regression of measurable disease and no new sites. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter, projected 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 19 |
Defined as the time from Day 1 of study drug administration to date of death from any cause. (NCT01626352)
Timeframe: every 3 cycles during treatment and every 3 months thereafter until progression or death from any cause, projected 18 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 12.0 |
Defined as the time from first treatment until objective tumor progression, relapse from complete response, or death from any cause. Tumor response is defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 8.6 |
Defined as the time from date of first treatment to the date of first documented disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 10.5 |
BMD was measured at the lumbosacral spine antero-posterior and at the femoral neck using a densitometer. A positive change from Baseline (increased bone density) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | grams/centimeters squared (g/cm^2) (Mean) | |||
|---|---|---|---|---|
| Spine, Baseline | Spine, Change from Baseline at Month12 | Femoral neck, Baseline | Femoral neck, Change from Baseline at Month 12 | |
| Control Arm | 0.93 | -0.002 | 0.73 | -0.03 |
| Teriparatide | 0.91 | 0.06 | 0.68 | 0.03 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and C-Reactive Protein (CRP) for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Month 12 | |
| Control Arm | 2.73 | -0.50 |
| Teriparatide | 2.66 | 0.42 |
Both hands were scanned using a CT scanner. A semi-automated software tool was used to segment the erosion margins in 3D. A board certified radiologist identified the individual erosions in six sub-regions: radius, ulna, proximal carpals, distal carpals, metacarpophalangeal (MCP) joints and proximal interphalangeal (PIP) joints. The average total in a single hand/wrist was calculated. A negative change from Baseline(less joint erosions) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12
| Intervention | cubic millimeter (mm^3) (Median) | |
|---|---|---|
| Baseline | Change from Baseline at Month 12 | |
| Control Arm | 571.4 | 9.1 |
| Teriparatide | 369.8 | -0.4 |
3 reviews available for prednisone and Aging
| Article | Year |
|---|---|
[Treatment of high-grade, disseminated non-Hodgkin's lymphoma in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Clinica | 2002 |
Methods for evaluating response to treatment in adult acute leukemia.
Topics: Acute Disease; Adult; Aging; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1983 |
Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations. Part IV: Multiple myeloma and Waldenström's macroglobulinemia.
Topics: Aging; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Diagnosis, Differential; | 1998 |
8 trials available for prednisone and Aging
| Article | Year |
|---|---|
Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.
Topics: Acyclovir; Aged; Aged, 80 and over; Aging; Anti-Infective Agents; Antibodies, Monoclonal, Murine-Der | 2014 |
Successful reduction of immunosuppression in older renal transplant recipients who exhibit donor-specific regulation.
Topics: Acute Disease; Aged; Aging; Animals; Calcineurin Inhibitors; Female; Follow-Up Studies; Graft Reject | 2009 |
CHOP and rituximab in elderly patients.
Topics: Aged; Aging; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2002 |
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).
Topics: Administration, Oral; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclop | 2005 |
Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age.
Topics: Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclop | 1984 |
Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis.
Topics: Adolescent; Adult; Aged; Aging; Asparaginase; Doxorubicin; Drug Therapy, Combination; Female; Humans | 1980 |
Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 1998 |
Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study.
Topics: Aged; Aging; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 2001 |
41 other studies available for prednisone and Aging
| Article | Year |
|---|---|
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Topics: Activities of Daily Living; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 2022 |
Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
Topics: Aged, 80 and over; Aging; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemothera | 2017 |
Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP.
Topics: Adult; Aged; Aging; Antibodies, Monoclonal, Murine-Derived; Antiemetics; Antineoplastic Combined Che | 2017 |
Usefulness of chemotherapy for the treatment of very elderly dogs with multicentric lymphoma.
Topics: Aging; Animals; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Do | 2018 |
Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus.
Topics: Adolescent; Adult; Age Factors; Aged; Aging; Antirheumatic Agents; Baltimore; Black or African Ameri | 2020 |
T cells increase before zoster and PD-1 expression increases at the time of zoster in immunosuppressed nonhuman primates latently infected with simian varicella virus.
Topics: Aging; Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Glucocorticoids; Herpes Zost | 2014 |
Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Murine-Derived; An | 2015 |
Canine epidermolysis bullosa acquisita: a retrospective study of 20 cases.
Topics: Aging; Animals; Dog Diseases; Dogs; Epidermolysis Bullosa Acquisita; Female; Immunologic Factors; Ma | 2015 |
[TECHNICAL INDICATIONS AND RESULTS OF CORTICOTHERAPY OF NEPHROTIC SYNDROMES IN ADULTS].
Topics: Adrenocorticotropic Hormone; Adult; Aging; Hematuria; Humans; Nephrotic Syndrome; Prednisone; Progno | 1964 |
ACUTE LEUKEMIA IN ADOLESCENTS AND ADULTS. RESULTS OF TREATMENT OVER THREE CONSECUTIVE 5-YEAR PERIODS.
Topics: Acute Disease; Adolescent; Adult; Aging; Cortisone; Drug Therapy; Humans; Leukemia; Mercaptopurine; | 1965 |
STUDIES OF PULSE WAVE VELOCITY IN POTENTIAL DIABETIC SUBJECTS.
Topics: Adolescent; Aging; Blood Pressure; Child; Diabetes Mellitus; Diagnosis; Genetics, Medical; Geriatric | 1965 |
Neurotologic issues.
Topics: Adult; Aged; Aging; Anti-Bacterial Agents; Anti-Inflammatory Agents; Autoantibodies; Autoimmune Dise | 2003 |
The in vivo effects of corticosteroids on thymocyte subsets in myasthenia gravis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aging; Antibodies, Monoclonal; Female; Humans; Male; Mid | 1984 |
Glucocorticoid receptors of human mononuclear leukocytes in vitro.
Topics: Adolescent; Adult; Aging; Cushing Syndrome; Dexamethasone; Female; Humans; Hyperthyroidism; Lymphocy | 1983 |
Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patients.
Topics: Actuarial Analysis; Adolescent; Adult; Aging; Bacterial Infections; Child; Drug Therapy, Combination | 1982 |
Results of induction therapy with vincristine and prednisone alone in adult acute lymphoblastic leukemia: report of 43 patients and review of the literature.
Topics: Adolescent; Adult; Aged; Aging; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Methotrexate; | 1982 |
An analysis of factors influencing the growth of children after renal transplantation.
Topics: Adolescent; Aging; Body Height; Child; Child, Preschool; Creatinine; Female; Glomerulonephritis; Gra | 1980 |
The effect of drugs on accumulation of exogenous norepinephrine by nervous tissue in vitro.
Topics: Aging; Animals; Biological Transport; Female; Histocytochemistry; Hydrocortisone; In Vitro Technique | 1980 |
Prednisolone disposition in steroid-dependent asthmatic children.
Topics: Aging; Asthma; Child; Dose-Response Relationship, Drug; Eosinophils; Female; Humans; Leukopenia; Mal | 1981 |
Influence of aging, localization, glucocorticoids and isotretinoin on matrix metalloproteases 2 (MMP-2) and 9 (MMP-9) in suction blister fluids.
Topics: Adult; Aged; Aged, 80 and over; Aging; Blister; Collagenases; Gelatinases; Humans; Isotretinoin; Mat | 1995 |
Kidney transplantation in the older patient.
Topics: Aged; Aging; Azathioprine; Cause of Death; Cyclosporine; Female; Florida; Follow-Up Studies; Graft R | 1994 |
Fractures in rheumatoid arthritis: an evaluation of associated risk factors.
Topics: Aging; Arthritis, Rheumatoid; Body Mass Index; Disabled Persons; Female; Fractures, Bone; Humans; Ma | 1993 |
Cromolyn increases strength in exercised mdx mice.
Topics: Aging; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Chymases; Creatine Kinase; Cromolyn | 1996 |
Outcome of planned pregnancies in systemic lupus erythematosus: a prospective study on 62 pregnancies.
Topics: Adrenal Cortex Hormones; Aging; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 1997 |
Management of cancer in the older person: a practical approach.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2000 |
The contribution of renal transplantation to final adult height: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).
Topics: Aging; Body Height; Child; Creatinine; Dose-Response Relationship, Drug; Female; Glucocorticoids; Hu | 2001 |
Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Aging; Base Sequence; Cells, Cultured; DNA Primers; Glu | 2002 |
Effect of 1alpha-hydroxycholecalciferol in senile osteoporosis and in bone loss following prednisone treatment.
Topics: Aged; Aging; Calcium; Humans; Hydroxycholecalciferols; Hydroxyproline; Osteoporosis; Prednisone | 1977 |
A controlled study of lymphocyte subsets in rheumatoid arthritis.
Topics: Aging; Antineoplastic Agents; Arthritis, Rheumatoid; Gold; Humans; Hydroxychloroquine; Lymphocyte Su | 1992 |
[Feasibility of CHOP chemotherapy--with special reference to age, diabetes mellitus, liver cirrhosis and obesity].
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 1989 |
Kinetics of prednisolone and endogenous cortisol suppression in the elderly.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aging; Chromatography, High Pressure Liquid; F | 1988 |
Familial juvenile onset of Bell's palsy.
Topics: Adolescent; Aging; Disease Susceptibility; Facial Paralysis; Female; Humans; Prednisone; Sex Factors | 1987 |
Influence of age at onset on the duration of treatment in idiopathic adult polymyositis and dermatomyositis.
Topics: Actuarial Analysis; Adult; Aged; Aging; Clinical Enzyme Tests; Creatine Kinase; Dermatomyositis; Fem | 1987 |
Chronic blisters on aging skin: causes and treatment.
Topics: Aged; Aging; Chronic Disease; Complement C3; Diagnosis, Differential; Humans; Immunoglobulin G; Immu | 1985 |
Joint and muscle pains in an aging tennis player.
Topics: Aging; Humans; Male; Middle Aged; Pain; Polymyalgia Rheumatica; Prednisone; Tennis | 1985 |
Polymyalgia rheumatica.
Topics: Aged; Aging; Blood Sedimentation; Female; Humans; Ibuprofen; Middle Aged; Polymyalgia Rheumatica; Pr | 1985 |
Effect of glucocorticoids upon the mucopolysaccharide content of human skin.
Topics: Adult; Aged; Aging; Biopsy; Collagen; Female; Glycosaminoglycans; Hexosamines; Humans; Male; Middle | 1966 |
Hemodialysis and renal transplantation in patients of the 50-80 age group.
Topics: Aged; Aging; Azathioprine; Blood Glucose; Cysts; Diabetes Mellitus; Female; Glomerulonephritis; Gluc | 1972 |
Glomerular enlargement in primary renal disease: a quantitative study.
Topics: Adolescent; Adult; Age Factors; Aging; Autopsy; Azathioprine; Biopsy; Child; Child, Preschool; Cyclo | 1974 |
The effect of ageing on prednisone-glucose tolerance and serum lipids.
Topics: Adipose Tissue; Adult; Aged; Aging; Blood Glucose; Cholesterol; Fatty Acids, Nonesterified; Female; | 1968 |
[The effect of prednisone on glycid metabolism in man during aging].
Topics: Adolescent; Adult; Aging; Carbohydrate Metabolism; Female; Glucose Tolerance Test; Humans; Male; Mid | 1966 |